Trazimera
Trazimera | |
---|---|
Term | Trazimera |
Short definition | Trazimera - (pronounced) (TRA-zih-MAYR-uh) A drug used alone or with other drugs to treat certain types of breast, stomach, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. |
Type | Cancer terms |
Specialty | Oncology |
Language | English |
Source | NCI |
Comments |
Trazimera - (pronounced) (TRA-zih-MAYR-uh) A drug used alone or with other drugs to treat certain types of breast, stomach, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trazimera attaches to a protein called HER2, which is found on some cancer cells. This can help the immune system kill cancer cells. Trazimera is a type of monoclonal antibody and a type of HER2 receptor antagonist. Also called Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant and Trastuzumab
External links
- Medical encyclopedia article on Trazimera
- Wikipedia's article - Trazimera
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski